<DOC>
	<DOCNO>NCT01349335</DOCNO>
	<brief_summary>To observe safety/efficacy tolvaptan treatment patient hepatic cirrhosis ascites explore dosage-effect relation drug .</brief_summary>
	<brief_title>Dose Exploring Setting Study Tolvaptan Treat Hepatic Cirrhosis With Ascites</brief_title>
	<detailed_description>Tolvaptan able exert hydragogue diuretic effect ( water diuresis ) via inhibition water reabsorption renal collecting duct without correspond increase electrolyte excretion . It confirm tolvaptan able increase urine volume without adverse effect renal function .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1. hepatic cirrhosis patient 7days treatment loop diuretic aldosterone antagonist still ascites 2 . Hospitalized patient hospitalize trial observation period posttherapeutic observation ( Visits clinic allow day 8 ) ; 3 . During observation period ( 3 day 1 day ) , subject whose body weight difference fall within ±1.0 kg range 2 day ( day2 day 1 ) prior initiation trial drug treatment ; 4 . Ages : ≥18 ≤75 year age ; 5 . Genders : men woman ; 6 . Signed Informed Consent Form . 1 . Patients follow disease , complication symptom : Hepatic encephalopathy ( Coma scale Note 1 ) grade 2 high ) ; Malignant ascites ; Uncontrolled spontaneous bacterial peritonitis ; Patients likely experience alimentary tract hemorrhage trial ; Heart failure ( NYHA cardiac function scale Note 2 ) stag 3 4 ) ; Anuria ( daily urine volume 100mL ) ; Dysuria result urethral stricture , calculus tumor . 2 . Patients follow medical history : Alimentary tract hemorrhage within 10 day prior screen ; Cerebrovascular accident within 1 month prior screen ; Gout attack within 1 month prior screen ; Past allergy hypersensitive reaction benzodiazepine ( e.g . benazepril hydrochloride ) 3 . Systolic pressure 90mmHg screening ; 4 . Patients follow abnormality laboratory examination screen : Serum creatinine exceed 2.5X upper limit normal , serum Na+ &gt; 145mmol/L ( exceeds upper limit normal ) , serum K+ &gt; 5.5mmol/L , uric acid &gt; 8.0mg/dL ( 476μmol/L ) , Childpugh scale great 12 . 5 . Patients take drug orally ; 6 . Pregnant breastfeeding patient woman childbearing age without take acceptable contraceptive measure ; 7 . Patients receive albumin blood preparation within 4 day prior trial drug administration ; 8 . Patients participate clinical trial drug within 1 month prior screen ; 9 . Patients participate tolvaptan trial take tolvaptan previously ; 10 . Patients unsuitable participate trial investigator ' opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>